| # | Pathway | Proteins |
|---|
| 1 | Vitamin digestion and absorption | ENSAPLP00000011529, ENSAPLP00000003561, ENSAPLP00000002020, ENSAPLP00000016339 |
| 2 | Amoebiasis | ENSAPLP00000012216, ENSAPLP00000010260, ENSAPLP00000011483, ENSAPLP00000012559, ENSAPLP00000010069, ENSAPLP00000002849, ENSAPLP00000002160, ENSAPLP00000013412 |
| 3 | Fat digestion and absorption | ENSAPLP00000011529, ENSAPLP00000003561, ENSAPLP00000002020, ENSAPLP00000016339 |
| 4 | ECM-receptor interaction | ENSAPLP00000010260, ENSAPLP00000011483, ENSAPLP00000013787, ENSAPLP00000012559, ENSAPLP00000004826, ENSAPLP00000010069, ENSAPLP00000002849 |
| 5 | Focal adhesion | ENSAPLP00000008057, ENSAPLP00000010260, ENSAPLP00000011483, ENSAPLP00000013787, ENSAPLP00000003050, ENSAPLP00000009311, ENSAPLP00000012559, ENSAPLP00000010069, ENSAPLP00000002849, ENSAPLP00000002160 |
| 6 | Salmonella infection | ENSAPLP00000009727, ENSAPLP00000003050, ENSAPLP00000015489, ENSAPLP00000009311, ENSAPLP00000006991 |
| 7 | Malaria | ENSAPLP00000016307, ENSAPLP00000007488, ENSAPLP00000011743 |
| 8 | African trypanosomiasis | ENSAPLP00000016307, ENSAPLP00000007488, ENSAPLP00000002020 |
| 9 | PI3K-Akt signaling pathway | ENSAPLP00000010260, ENSAPLP00000011483, ENSAPLP00000013787, ENSAPLP00000003050, ENSAPLP00000012022, ENSAPLP00000012559, ENSAPLP00000007187, ENSAPLP00000010069, ENSAPLP00000002849 |
| 10 | Carbon metabolism (no map in kegg database) | ENSAPLP00000009916, ENSAPLP00000015938, ENSAPLP00000003377, ENSAPLP00000005996, ENSAPLP00000003424, ENSAPLP00000005784, ENSAPLP00000008955, ENSAPLP00000010482 |
| 11 | Proteoglycans in cancer | ENSAPLP00000008057, ENSAPLP00000011483, ENSAPLP00000013972, ENSAPLP00000013787, ENSAPLP00000003050, ENSAPLP00000009311, ENSAPLP00000012559, ENSAPLP00000004826 |
| 12 | Fatty acid degradation | ENSAPLP00000015938, ENSAPLP00000003377, ENSAPLP00000008299, ENSAPLP00000010482 |
| 13 | beta-Alanine metabolism | ENSAPLP00000003377, ENSAPLP00000008299, ENSAPLP00000010482 |
| 14 | Small cell lung cancer | ENSAPLP00000010260, ENSAPLP00000012559, ENSAPLP00000010069, ENSAPLP00000002849 |
| 15 | Legionellosis | ENSAPLP00000000447, ENSAPLP00000004358, ENSAPLP00000015167 |
| 16 | Lysine degradation | ENSAPLP00000003377, ENSAPLP00000008299, ENSAPLP00000008955 |
| 17 | Monobactam biosynthesis | ENSAPLP00000005827 |
| 18 | Glycolysis / Gluconeogenesis | ENSAPLP00000006919, ENSAPLP00000009916, ENSAPLP00000008299, ENSAPLP00000005784 |
| 19 | Valine, leucine and isoleucine degradation | ENSAPLP00000015938, ENSAPLP00000003377, ENSAPLP00000008299, ENSAPLP00000010482 |
| 20 | Complement and coagulation cascades | ENSAPLP00000010484, ENSAPLP00000005849, ENSAPLP00000006069, ENSAPLP00000015167 |
| 21 | Glycerolipid metabolism | ENSAPLP00000006919, ENSAPLP00000008299 |
| 22 | Vascular smooth muscle contraction | ENSAPLP00000008057, ENSAPLP00000015489, ENSAPLP00000006991, ENSAPLP00000015007 |
| 23 | Toxoplasmosis | ENSAPLP00000010260, ENSAPLP00000000447, ENSAPLP00000010069, ENSAPLP00000002849 |
| 24 | Cardiac muscle contraction | ENSAPLP00000012136, ENSAPLP00000011162, ENSAPLP00000014736 |
| 25 | Regulation of actin cytoskeleton | ENSAPLP00000009727, ENSAPLP00000008057, ENSAPLP00000003050, ENSAPLP00000015489, ENSAPLP00000012559, ENSAPLP00000006991, ENSAPLP00000002160 |
| 26 | Pentose and glucuronate interconversions | ENSAPLP00000006919, ENSAPLP00000008299 |
| 27 | PPAR signaling pathway | ENSAPLP00000005715, ENSAPLP00000002020, ENSAPLP00000010482 |
| 28 | Protein digestion and absorption | ENSAPLP00000011483, ENSAPLP00000012993, ENSAPLP00000011162 |
| 29 | Fatty acid metabolism (no map in kegg database) | ENSAPLP00000015938, ENSAPLP00000003377, ENSAPLP00000010482 |
| 30 | Mineral absorption | ENSAPLP00000009906, ENSAPLP00000011162 |
| 31 | Tuberculosis | ENSAPLP00000009762, ENSAPLP00000004358, ENSAPLP00000015167, ENSAPLP00000013412 |
| 32 | Butanoate metabolism | ENSAPLP00000015938, ENSAPLP00000003377 |
| 33 | Pathways in cancer | ENSAPLP00000010260, ENSAPLP00000004505, ENSAPLP00000013972, ENSAPLP00000003050, ENSAPLP00000012022, ENSAPLP00000012559, ENSAPLP00000010069, ENSAPLP00000002849 |
| 34 | Degradation of aromatic compounds (no map in kegg database) | ENSAPLP00000006919 |
| 35 | Cyanoamino acid metabolism | ENSAPLP00000003424 |
| 36 | Tryptophan metabolism | ENSAPLP00000003377, ENSAPLP00000008299 |
| 37 | GABAergic synapse | ENSAPLP00000012022, ENSAPLP00000003730 |
| 38 | cAMP signaling pathway | ENSAPLP00000008057, ENSAPLP00000003050, ENSAPLP00000011162 |
| 39 | Pancreatic secretion | ENSAPLP00000003050, ENSAPLP00000011162 |
| 40 | Selenocompound metabolism | ENSAPLP00000005827 |
| 41 | Sulfur metabolism | ENSAPLP00000005827 |
| 42 | Type I diabetes mellitus | ENSAPLP00000004358 |
| 43 | Endocytosis | ENSAPLP00000000447, ENSAPLP00000005705, ENSAPLP00000010989, ENSAPLP00000003542, ENSAPLP00000016193, ENSAPLP00000008982, ENSAPLP00000013412 |
| 44 | Influenza A | ENSAPLP00000000447, ENSAPLP00000003582, ENSAPLP00000009427 |
| 45 | Propanoate metabolism | ENSAPLP00000003377, ENSAPLP00000010482 |
| 46 | Pentose phosphate pathway | ENSAPLP00000009916, ENSAPLP00000005996 |
| 47 | Ether lipid metabolism | ENSAPLP00000015568 |
| 48 | Ascorbate and aldarate metabolism | ENSAPLP00000008299 |
| 49 | cGMP-PKG signaling pathway | ENSAPLP00000008057, ENSAPLP00000009427, ENSAPLP00000011162 |
| 50 | Ribosome biogenesis in eukaryotes | ENSAPLP00000013734, ENSAPLP00000003582 |
| 51 | Glutathione metabolism | ENSAPLP00000004505, ENSAPLP00000005996 |
| 52 | Parkinson's disease | ENSAPLP00000008543, ENSAPLP00000009427, ENSAPLP00000010540, ENSAPLP00000014736 |
| 53 | Adrenergic signaling in cardiomyocytes | ENSAPLP00000008057, ENSAPLP00000012136, ENSAPLP00000011162 |
| 54 | Carbohydrate digestion and absorption | ENSAPLP00000011162 |
| 55 | Proximal tubule bicarbonate reclamation | ENSAPLP00000011162 |
| 56 | One carbon pool by folate | ENSAPLP00000003424 |
| 57 | Citrate cycle (TCA cycle) | ENSAPLP00000005784, ENSAPLP00000008955 |
| 58 | Viral carcinogenesis | ENSAPLP00000003050, ENSAPLP00000007187, ENSAPLP00000002160, ENSAPLP00000015167 |
| 59 | Herpes simplex infection | ENSAPLP00000014318, ENSAPLP00000008057, ENSAPLP00000015167 |
| 60 | Prion diseases | ENSAPLP00000000447, ENSAPLP00000002849 |
| 61 | Ras signaling pathway | ENSAPLP00000003050, ENSAPLP00000012022, ENSAPLP00000013412 |
| 62 | Non-alcoholic fatty liver disease (NAFLD) | ENSAPLP00000008543, ENSAPLP00000003050, ENSAPLP00000014736 |
| 63 | Aldosterone-regulated sodium reabsorption | ENSAPLP00000011162 |
| 64 | Pyruvate metabolism | ENSAPLP00000008299, ENSAPLP00000005784 |
| 65 | Glycosaminoglycan degradation | ENSAPLP00000008654 |
| 66 | Histidine metabolism | ENSAPLP00000008299 |
| 67 | Biosynthesis of unsaturated fatty acids (no map in kegg database) | ENSAPLP00000003377 |
| 68 | Renin-angiotensin system | ENSAPLP00000015747 |
| 69 | Leukocyte transendothelial migration | ENSAPLP00000013972, ENSAPLP00000003050, ENSAPLP00000002160 |
| 70 | Bile secretion | ENSAPLP00000011162 |
| 71 | Regulation of lipolysis in adipocytes | ENSAPLP00000005715 |
| 72 | Bladder cancer | ENSAPLP00000013972 |
| 73 | Sphingolipid signaling pathway | ENSAPLP00000009762, ENSAPLP00000003050 |
| 74 | Shigellosis | ENSAPLP00000009727, ENSAPLP00000003050 |
| 75 | Oocyte meiosis | ENSAPLP00000008057, ENSAPLP00000007187 |
| 76 | Estrogen signaling pathway | ENSAPLP00000000447, ENSAPLP00000013972 |
| 77 | Tight junction | ENSAPLP00000015489, ENSAPLP00000006991, ENSAPLP00000002160 |
| 78 | Metabolism of xenobiotics by cytochrome P450 | ENSAPLP00000004505 |
| 79 | Drug metabolism - cytochrome P450 | ENSAPLP00000004505 |
| 80 | Fatty acid elongation | ENSAPLP00000003377 |
| 81 | Systemic lupus erythematosus | ENSAPLP00000002160, ENSAPLP00000015167 |
| 82 | Wnt signaling pathway | ENSAPLP00000002426, ENSAPLP00000003050 |
| 83 | MAPK signaling pathway | ENSAPLP00000000447, ENSAPLP00000003050, ENSAPLP00000009311 |
| 84 | Insulin secretion | ENSAPLP00000011162 |
| 85 | Hepatitis B | ENSAPLP00000013972, ENSAPLP00000004826 |
| 86 | Hippo signaling pathway | ENSAPLP00000008057, ENSAPLP00000007187 |
| 87 | Adherens junction | ENSAPLP00000003050, ENSAPLP00000002160 |
| 88 | Amphetamine addiction | ENSAPLP00000008057 |
| 89 | Phagosome | ENSAPLP00000003050, ENSAPLP00000015167, ENSAPLP00000013412 |
| 90 | Alzheimer's disease | ENSAPLP00000008543, ENSAPLP00000011743, ENSAPLP00000014736 |
| 91 | Neurotrophin signaling pathway | ENSAPLP00000003050, ENSAPLP00000007187 |
| 92 | Dopaminergic synapse | ENSAPLP00000008057, ENSAPLP00000012022 |
| 93 | Chemical carcinogenesis | ENSAPLP00000004505 |
| 94 | Leishmaniasis | ENSAPLP00000015167 |
| 95 | Glycine, serine and threonine metabolism | ENSAPLP00000003424 |
| 96 | Colorectal cancer | ENSAPLP00000003050 |
| 97 | Renin secretion | ENSAPLP00000015747 |
| 98 | Alcoholism | ENSAPLP00000008057, ENSAPLP00000012022 |
| 99 | Pancreatic cancer | ENSAPLP00000003050 |
| 100 | Staphylococcus aureus infection | ENSAPLP00000015167 |
| 101 | Starch and sucrose metabolism | ENSAPLP00000009916 |
| 102 | Morphine addiction | ENSAPLP00000012022 |
| 103 | VEGF signaling pathway | ENSAPLP00000003050 |
| 104 | Toll-like receptor signaling pathway | ENSAPLP00000003050 |
| 105 | Jak-STAT signaling pathway | ENSAPLP00000010107 |
| 106 | Vasopressin-regulated water reabsorption | ENSAPLP00000013412 |
| 107 | Amyotrophic lateral sclerosis (ALS) | ENSAPLP00000003050 |
| 108 | Pertussis | ENSAPLP00000015167 |
| 109 | Endocrine and other factor-regulated calcium reabsorption | ENSAPLP00000011162 |
| 110 | B cell receptor signaling pathway | ENSAPLP00000003050 |
| 111 | Long-term potentiation | ENSAPLP00000008057 |
| 112 | Epstein-Barr virus infection | ENSAPLP00000000447, ENSAPLP00000003582, ENSAPLP00000007187 |
| 113 | Purine metabolism | ENSAPLP00000008550, ENSAPLP00000005827 |
| 114 | Amino sugar and nucleotide sugar metabolism | ENSAPLP00000009916 |
| 115 | Inflammatory mediator regulation of TRP channels | ENSAPLP00000008057 |
| 116 | Chemokine signaling pathway | ENSAPLP00000003050, ENSAPLP00000012022 |
| 117 | Central carbon metabolism in cancer | ENSAPLP00000005784 |
| 118 | Transcriptional misregulation in cancer | ENSAPLP00000013972 |
| 119 | Thyroid hormone synthesis | ENSAPLP00000011162 |
| 120 | TNF signaling pathway | ENSAPLP00000013972 |
| 121 | Choline metabolism in cancer | ENSAPLP00000003050 |
| 122 | Retrograde endocannabinoid signaling | ENSAPLP00000012022 |
| 123 | Bacterial invasion of epithelial cells | ENSAPLP00000003050, ENSAPLP00000012559 |
| 124 | Natural killer cell mediated cytotoxicity | ENSAPLP00000003050 |
| 125 | Renal cell carcinoma | ENSAPLP00000003050 |
| 126 | Fc epsilon RI signaling pathway | ENSAPLP00000003050 |
| 127 | Prostate cancer (no map in kegg database) | ENSAPLP00000004505 |
| 128 | Glyoxylate and dicarboxylate metabolism | ENSAPLP00000003424 |
| 129 | Salivary secretion | ENSAPLP00000011162 |
| 130 | Arginine and proline metabolism | ENSAPLP00000008299 |
| 131 | Glutamatergic synapse | ENSAPLP00000012022 |
| 132 | Metabolic pathways (no map in kegg database) | ENSAPLP00000006919, ENSAPLP00000009916, ENSAPLP00000008543, ENSAPLP00000015938, ENSAPLP00000003377, ENSAPLP00000008299, ENSAPLP00000008550, ENSAPLP00000005996, ENSAPLP00000003424, ENSAPLP00000005827, ENSAPLP00000005784, ENSAPLP00000008955, ENSAPLP00000010482, ENSAPLP00000014736, ENSAPLP00000008654 |
| 133 | Viral myocarditis | ENSAPLP00000003050 |
| 134 | Measles | ENSAPLP00000000447 |
| 135 | Antigen processing and presentation | ENSAPLP00000000447 |
| 136 | HTLV-I infection | ENSAPLP00000003582, ENSAPLP00000009427 |
| 137 | Gastric acid secretion | ENSAPLP00000011162 |
| 138 | Platelet activation | ENSAPLP00000008057, ENSAPLP00000011483 |
| 139 | Circadian entrainment | ENSAPLP00000012022 |
| 140 | Cholinergic synapse | ENSAPLP00000012022 |
| 141 | Insulin resistance | ENSAPLP00000008057 |
| 142 | Epithelial cell signaling in Helicobacter pylori infection | ENSAPLP00000003050 |
| 143 | Huntington's disease | ENSAPLP00000008543, ENSAPLP00000009427, ENSAPLP00000014736 |
| 144 | Oxidative phosphorylation | ENSAPLP00000008543, ENSAPLP00000014736 |
| 145 | Osteoclast differentiation | ENSAPLP00000003050 |
| 146 | Chagas disease (American trypanosomiasis) | ENSAPLP00000015167 |
| 147 | Hippo signaling pathway - fly | ENSAPLP00000007187 |
| 148 | Serotonergic synapse | ENSAPLP00000012022 |
| 149 | Cell cycle | ENSAPLP00000007187 |
| 150 | RNA degradation | ENSAPLP00000004358 |
| 151 | Rap1 signaling pathway | ENSAPLP00000009727, ENSAPLP00000003050 |
| 152 | Peroxisome | ENSAPLP00000006873 |
| 153 | Glucagon signaling pathway | ENSAPLP00000005784 |
| 154 | Lysosome | ENSAPLP00000009762, ENSAPLP00000008654 |
| 155 | Thyroid hormone signaling pathway | ENSAPLP00000011162 |
| 156 | Protein processing in endoplasmic reticulum | ENSAPLP00000000447, ENSAPLP00000014094 |
| 157 | mRNA surveillance pathway | ENSAPLP00000008057 |
| 158 | Fc gamma R-mediated phagocytosis | ENSAPLP00000003050 |
| 159 | HIF-1 signaling pathway | ENSAPLP00000005784 |
| 160 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ENSAPLP00000002160 |
| 161 | Ubiquitin mediated proteolysis | ENSAPLP00000000719 |
| 162 | Axon guidance | ENSAPLP00000003050 |
| 163 | Hypertrophic cardiomyopathy (HCM) | ENSAPLP00000012136 |
| 164 | Calcium signaling pathway | ENSAPLP00000009427 |
| 165 | Dilated cardiomyopathy | ENSAPLP00000012136 |
| 166 | Ribosome | ENSAPLP00000016333, ENSAPLP00000010726 |
| 167 | Spliceosome | ENSAPLP00000014318, ENSAPLP00000000447 |
| 168 | Oxytocin signaling pathway | ENSAPLP00000008057 |
| 169 | Biosynthesis of amino acids (no map in kegg database) | ENSAPLP00000003424 |
| 170 | Insulin signaling pathway | ENSAPLP00000008057 |
| 171 | MicroRNAs in cancer | ENSAPLP00000013972 |
| 172 | RNA transport | ENSAPLP00000003582 |